TNBC Clinical Trials in St Louis, Missouri
9 recruitingSt Louis, Missouri
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1Phase 2
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Triple Negative Breast Cancer(TNBC)HR+ Breast CancerHR+/HER2- Breast Cancer+1 more
NiKang Therapeutics, Inc.361 enrolled14 locationsNCT07029399
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 1
Study of XB010 in Subjects With Solid Tumors
Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1Phase 2
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Solid TumorsER+ Breast CancerTriple Negative Breast Cancer(TNBC)+2 more
Jacobio Pharmaceuticals Co., Ltd.102 enrolled8 locationsNCT05490472
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Liver CancerColorectal, CancerEndometrial Cancer+12 more
Elephas2,000 enrolled8 locationsNCT07327489
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793